This article is more than 5 years old. Information may no longer be current.
VIDEO: CAR-T cell therapy may target EGFR variant III in glioblastoma
NEW ORLEANS — Marcela V. Maus, MD, PhD, director of cellular immunotherapy at Massachusetts General Hospital Cancer Center, spoke with HemOnc Today about a study she presented at the American Association for Cancer Research Annual Meeting that assessed use of genetically modified chimeric antigen T-cell receptors targeted against EGFR variant III to treat patients with glioblastoma.
“We’re encouraged by the fact that T cells were able to traffic to the brain tumor itself and affect antigen loss,” Maus told HemOnc Today. “This really opens up the use of T cells as therapies for diseases like glioblastoma, where just getting through into the tumor — past the blood–brain barrier – is a significant achievement.”